Business Context and Reporting Period
Company: Accuray Incorporated
Filing Type: Form 8-K (Current Report)
Date of Report: December 21, 2012
Event: Entry into a Material Definitive Agreement regarding the divestiture of Compact Particle Acceleration Corporation (CPAC).
Key Financial Metrics
This filing is a Current Report (Form 8-K) and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for the purchase price or specific financial impact of the transaction.
Material Changes
On December 21, 2012, Accuray entered into a Purchase Agreement and Release with CPAC, an entity established in 2008 by TomoTherapy Incorporated (a wholly-owned subsidiary of Accuray). Under this agreement:
- Accuray will sell all equity securities and convertible securities of CPAC held by Accuray.
- Accuray will sell all notes representing indebtedness owed from CPAC to Accuray.
- Accuray will transfer all rights under the Limited Exclusive Patent License Agreement dated February 23, 2007.
- The transaction involves the exchange of certain waivers and releases by each party.
Guidance, Outlook, and Risks
Management Commentary: The filing summarizes the transaction previously disclosed in an April 2012 Form 8-K. The full Purchase Agreement and Release will be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ended December 31, 2012.
Risks/Contingencies: The securities offered and sold pursuant to the agreement were not registered under the Securities Act of 1933. The summary is qualified in its entirety by the complete text of the agreement.
Investor Verification Checklist
- Verify the specific purchase price and consideration details in the upcoming Form 10-Q exhibit.
- Review the full text of the Purchase Agreement and Release for specific waiver and release terms.
- Confirm the accounting treatment and potential gain or loss on the divestiture in the Q4 2012 financial results.
- Assess the strategic impact of exiting the compact proton therapy system development via CPAC.